Athero Review - Issue 2/2023
Guidelines
66
Statement CSAT on Consensus statement of the European Atherosclerosis Society: Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis
Michal Vrablík, Vladimír Bláha, Renata Cífková, Tomáš Freiberger, David Karásek, Pavel Kraml, Jan Piťha, Hana Rosolová, Vladimír Soška, Tomáš Štulc, Lukáš Zlatohlávek Za Výbor Čsat, Jana Mašková
Reviews
77
85
95
Genetic testing – polygenic score
Jaroslav A. Hubáček
103
109
Hyperlipidemic crisis as a risk factor for acute pancreatitis
Martin Bajer, Jo O Fortunato, Jan Maňák, Vladimír Bláha
112
An unconventional manifestation of severe hypercholesterolemia – sudden senzorineural hearing loss? Case report
Miriam Kozárová, Zuzana Kozelová
Personal News
121
Comments to recent literature of interest
Eva Tůmová
Announcements
117
Inclisiran receives reimbursement and enters clinical practice
Kristýna Čillíková
Athero Review
2023 Číslo 2
Najčítanejšie v tomto čísle
- Bempedoic acid in the context of current hypolipidemic treatment options and the results of the CLEAR OUTCOMES trial
- Statement CSAT on Consensus statement of the European Atherosclerosis Society: Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis
- The importance of nonstatin therapies for LDL-cholesterol lowering in the management of very high and high atherosclerotic cardiovascular risk
- Hyperlipidemic crisis as a risk factor for acute pancreatitis